June 2018: New capital of CHF 10.25 million
The 2018 capital increase was closed on May 31 with subscriptions in the amount of CHF 10.25 million. As in previous financing rounds, we were able to substantially expand our shareholder base also this year and now count around 640 shareholders. We are very pleased with the great interest in our oncology project. We would like to welcome the 174 new shareholders at InnoMedica and also to thank the 124 existing shareholders who have further expanded their commitment.
The newly created capital allows the expansion of the production facility in Marly, allowing Talidox to be produced in sufficient quantities for market entry after a successful clinical study. At the same time, we will also drive forward the development of our innovative pipeline products, particularly in neurology with further preclinical studies and the toxicology study for Talineuren.